Business Wire

FONDATION-IPSEN

19.11.2016 16:21:30 CET | Business Wire | Press release

Share
The 21st Longevity Prize of the Fondation Ipsen will be awarded to Kaare Christensen

The Fondation IPSEN Longevity Prize will be given this year at the GSA meeting (Gerontological Society of America), in New Orleans on November 19th, 2016. The international jury chaired by Professor Thomas Kirkwood (Newcastle University, UK and Copenhagen University, Denmark), have unanimously decided to award the prize to Kaare Christensen for his pioneering work on the importance of genes and environment in aging and longevity.

Kaare Christensen, MD, PhD, DRMSC, is Professor of Epidemiology at the University of Southern Denmark and Senior Research Scientist at the Terry Sanford Institute, Duke University, North Carolina, USA. Dr. Christensen is the Director of the Danish Twin Registry and the Danish Aging Research Center. He has conducted a long series of studies among twins and the oldest-old in order to shed light on the importance of genes and environment in aging and longevity. Furthermore, he has a longstanding interest in the relation between early life events and later life health outcome.

Abstract of his lecture: “Is Mortality written on the face? Or Elsewhere?”

Predicting length of life is of interest to individuals, medical doctors, demographers and researchers on aging. While most people would probably be uncomfortable with an exact prediction at an individual level (if that were possible), the identification of factors associated with health and survival can potentially provide the basis for decision making, interventions and public health initiatives. A series of “the usual suspects” is known to be associated with health and survival, e.g. birth cohort, gender, smoking and other life style factors, genetics, early life and socioeconomic factors. Over the last decades, this list has been extended with biomarkers of aging that include performance measures and molecular markers such as leukocyte telomere length and DNA methylation age. We have used nationwide cohort studies of twins, oldest-old individuals and long-lived families in Denmark to understand variance in health and survival and to identify clinically useful biomarkers of aging. Perhaps surprisingly, we have found that among the elderly, simple, low-tech biomarkers, including perceived age based on photos, are among the most powerful indicators of aging.

The Longevity Prize

Created in 1996, this Prize of the Fondation Ipsen has been awarded every year to renowned specialists in Longevity:

Caleb E. Finch (University of Southern California, Los Angeles, USA), Vaïno Kannisto (Odense University, Denmark) , Roy L. Walford (formerly University of California Los Angeles, USA), John E. Morley (St. Louis University, USA), Paul B. and Margret M. Baltes (formerly Free University of Berlin, Germany), Justin D. Congdon (University of Georgia, Aiken, USA), George M. Martin (University of Washington, Seattle, USA), James W. Vaupel (Max-Planck Institute for Demographic Research, Rostock, Germany), Linda Partridge (University College London, UK), Sir Michael Marmot (University College London, UK), Cynthia Kenyon (University of California, San Francisco, USA), David J.P. Barker (University of Southampton, UK), Gerald McClearn (Pennsylvania State University, University Park, USA), Jacques Vallin (French National Institute of Demography, Paris, France), Judith Campisi (Buck Institute for Age Research, Novato, USA), Thomas Kirkwood (Newcastle University, Newcastle upon Tyne, UK), Linda Fried (Columbia University, New York, USA), Gary Ruvkun (Harvard Medical School - CCIB, Boston, US), Luigi Ferrucci (National Institute on Aging, NIH, Baltimore, USA) and Steven N. Austad (University of Alabama at Birmingham, USA).

Members of the jury

Thomas Kirkwood, President (Newcastle University, UK Copenhagen University, Denmark), Judith Campisi (Buck Institute for Research on Aging, Novato, USA), Eileen Crimmins (University of Southern California, Los Angeles, USA), Caleb Finch (University of Southern California, Los Angeles, USA), Bernard Jeune* (University of Southern Denmark, Odense, Denmark), George Martin* (University of Washington, Seattle, USA), Yasuyuki Gondo (Osaka University, Japan), Jean-Marie Robine (INSERM, Démographie et Santé, Montpellier, France), Bruno Vellas (University of Toulouse, France), Marja Jylhä (University of Tampere, Finland), Steven N. Austad (University of Alabama at Birmingham, USA), Luigi Ferrucci (National Institute on Aging, Baltimore, USA) and a Fondation IPSEN representative.

(* Former Jury Members).

The Fondation IPSEN

Established in 1983 under the aegis of the Fondation de France, the ambition of the Fondation IPSEN is to initiate a reflection about the major scientific issues of the forthcoming years. The long-standing mission of the Fondation IPSEN is to contribute to the development and dissemination of scientific knowledge by fostering interaction between scientists and clinicians. It has developed an important international network of scientific experts who meet regularly at meetings known as Colloques Médecine et Recherche, dedicated to three main topics: neurosciences, endocrinology and cancer science. Moreover the Fondation IPSEN has started several series of meetings in partnership with the Salk Institute, the Karolinska Institute as well as with the science journals Cell and Science. The Fondation IPSEN produced several hundred publications and more than 250 scientists have been awarded prizes and grants.

www.fondation-ipsen.org

Contact:

Image Sept
Isabelle de Segonzac, +33 (0)1 53 70 74 70
isegonzac@image7.fr

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Allianz Delivers Record Nine-month Result of 14.1 Billion Euros and Raises 2026 Outlook12.11.2026 07:06:00 CET | Press release

3Q 2026 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111915059/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Total business volume at 44.4 billion euros, an internal growth of 3.0 percent1. Excellent contribution from Asset Management and good internal growth in Property-Casualty. Operating profit rises 6.2 percent to 4.7 billion euros, driven by an outstanding result from the Asset Management segment, attributable to higher business volume and margins, and a strong contribution from Life/Health. Shareholders’ core net income increases 1.2 percent to 2.9 billion euros. Adjusted for offsetting measures following the sale of the stake in our Indian JVs, underlying growth is 3 percent. 9M 2026 Total business volume at 143.0 billion euros, an internal growth of 3.8 percent 1 , driven by excellent growth in Asset Management and good internal growth in Property-Casualty. Operating profit rises 7.8 percent to 14.1 bil

LTM Brings AI-Powered Quantum Error Mitigation to IBM Quantum Functions Catalog12.11.2026 06:30:00 CET | Press release

LTM, the Business Creativity partner to the world’s largest enterprises, today announced that AI-QEM, its proprietary AI-powered Quantum Error Mitigation capability, is now available in the IBM Quantum Functions Catalog. With this milestone, LTM becomes the first Global Systems Integrator (GSI) worldwide to publish a function in the catalog. The IBM Quantum Functions Catalog is an ecosystem of partner-built quantum software services that simplify quantum workflows and enable researchers and enterprises to run quantum experiments more efficiently for algorithm development and application prototyping. AI-QEM is available as a circuit function, allowing users of eligible IBM Quantum access plans to apply LTM's error mitigation capability directly within their Qiskit workflows. Quantum computers are inherently susceptible to noise and errors that can impact computational outcomes. While conventional error mitigation techniques often require additional circuit executions, quantum processing

Access Advance Announces New Effective Discount Rates for Its Multi-Codec Bridging Agreement, Starting on January 1, 202711.11.2026 20:18:00 CET | Press release

Access Advance LLC today announced that the Licensors of the HEVC Advance and VVC Advance Patent Pools have independently approved a two-step, phased reduction in the effective royalty discount available under the Multi-Codec Bridging Agreement (MCBA) for Licensees of both pools who sign the MCBA on or after January 1, 2027. Licensees that join both the HEVC Advance and VVC Advance Patent Pools and execute the MCBA on or before December 31, 2026, will secure the current MCBA rates, resulting in an effective discount of up to 50%. Licensees that sign on or after January 1, 2027 will receive a reduced discount as further described below. The MCBA is an administrative agreement, not a separate license, that lets Licensees of both HEVC Advance and VVC Advance Patent Pools pay a single, reduced royalty rate for products that include both HEVC and VVC codecs. Today the MCBA rate for a dual-codec product is the same as the VVC Advance single codec product rate; up to 50% of what a Licensee wo

Angel Aligner Unveils Six Innovations for 202711.11.2026 17:23:00 CET | Press release

Angel Elevates the Orthodontic Specialty by Focusing on Complex-Case Solutions Angelalign Technology Inc. (6699.HK) (“Angel”), a global clear aligner leader, has unveiled six new clinical innovations, including SuperElastic (MC-SE)* aligner material, a Deepbite Solution for significantly expanded indications, and the Adapt-MATMsystem for next generation growth guidance for young patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110338654/en/ Unveiling Angel's 2027 Innovations. Orthodontists and opinion leaders have long remarked about Angel’s clinical excellence. Orthodontics educator and thought leader Dr. David Sarver said: “In over 4 decades, I’ve never had a parent say I’d be happy if you ensure that my child’s treatment results are average.” Angel is committed to elevating the orthodontic specialty well above the average, especially as more competition and harder referral cases demand outstanding results. Bind

Abu Dhabi Future Health Summit Concludes with Research Partnerships and New Programmes to Advance Prevention and Health Innovation11.11.2026 15:58:00 CET | Press release

Partnerships span drug discovery, clinical research, preventive and reproductive health Launch of an AI Clinician Framework and a Trusted Research Environment for health and genomic data Four whitepapers address genomics, therapeutics, fertility and wearable technologies New programmes support health innovators and entrepreneurs More than 17,300 visitors from 85 countries, with 130 speakers across 45 sessions Held under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council, Abu Dhabi Future Health Summit 2026 concluded with agreements and initiatives spanning drug discovery, clinical research, preventive and reproductive health, alongside research and entrepreneurship programmes that will sustain collaboration beyond the Summit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111545964/en/ The Summit is the annual flagship gath

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye